UCB SA (UCBJF)
USD 195.88
(0.0%)
USD 195.88
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.26 Billion EUR | -23.8% |
| 2022 | 1.17 Billion EUR | -18.03% |
| 2021 | 1.59 Billion EUR | 10.22% |
| 2020 | 1.3 Billion EUR | 5.39% |
| 2019 | 1.33 Billion EUR | -4.43% |
| 2018 | 1.39 Billion EUR | 7.2% |
| 2017 | 1.3 Billion EUR | 15.79% |
| 2016 | 1.02 Billion EUR | 26.49% |
| 2015 | 762 Million EUR | 50.51% |
| 2014 | 600 Million EUR | -20.64% |
| 2013 | 544 Million EUR | 19.94% |
| 2012 | 637 Million EUR | -16.62% |
| 2011 | 614 Million EUR | 2.05% |
| 2010 | 468 Million EUR | -44.41% |
| 2009 | 1.11 Billion EUR | 74.63% |
| 2008 | 321 Million EUR | 6.96% |
| 2007 | 545 Million EUR | 0.28% |
| 2006 | 678 Million EUR | 18.98% |
| 2005 | 502 Million EUR | -28.88% |
| 2004 | 355 Million EUR | 4.01% |
| 2003 | 797.61 Million EUR | -15.45% |
| 2002 | 829.74 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 322 Million EUR | -41.67% |
| 2024 Q2 | 322 Million EUR | 0.0% |
| 2023 Q3 | 270.5 Million EUR | -65.93% |
| 2023 Q1 | 364 Million EUR | -17.27% |
| 2023 FY | - EUR | -23.8% |
| 2023 Q4 | 552 Million EUR | 104.07% |
| 2023 Q2 | 794 Million EUR | 118.13% |
| 2022 Q4 | 440 Million EUR | 0.0% |
| 2022 Q2 | 809 Million EUR | 121.34% |
| 2022 Q1 | 365.5 Million EUR | -52.78% |
| 2022 FY | - EUR | -18.03% |
| 2021 FY | - EUR | 10.22% |
| 2021 Q4 | 774 Million EUR | 106.95% |
| 2021 Q3 | 374 Million EUR | -56.05% |
| 2021 Q2 | 851 Million EUR | 101.42% |
| 2021 Q1 | 422.5 Million EUR | -35.3% |
| 2020 Q2 | 779 Million EUR | 98.22% |
| 2020 Q4 | 653 Million EUR | 134.89% |
| 2020 Q1 | 393 Million EUR | -42.96% |
| 2020 FY | - EUR | 5.39% |
| 2020 Q3 | 278 Million EUR | -64.31% |
| 2019 Q4 | 689 Million EUR | 0.0% |
| 2019 FY | - EUR | -4.43% |
| 2019 Q1 | 358.5 Million EUR | 0.0% |
| 2019 Q2 | 708 Million EUR | 97.49% |
| 2018 Q2 | 398 Million EUR | 0.0% |
| 2018 FY | - EUR | 7.2% |
| 2018 Q1 | 398 Million EUR | 34.23% |
| 2017 FY | - EUR | 15.79% |
| 2017 Q2 | 339 Million EUR | 0.0% |
| 2017 Q1 | 339 Million EUR | 40.66% |
| 2017 Q4 | 296.5 Million EUR | 0.0% |
| 2017 Q3 | 296.5 Million EUR | -12.54% |
| 2016 Q1 | 273 Million EUR | 44.44% |
| 2016 FY | - EUR | 26.49% |
| 2016 Q3 | 241 Million EUR | -11.72% |
| 2016 Q4 | 241 Million EUR | 0.0% |
| 2016 Q2 | 273 Million EUR | 0.0% |
| 2015 Q4 | 189 Million EUR | 0.0% |
| 2015 Q1 | 225.5 Million EUR | 54.98% |
| 2015 Q2 | 225.5 Million EUR | 0.0% |
| 2015 Q3 | 189 Million EUR | -16.19% |
| 2015 FY | - EUR | 50.51% |
| 2014 Q1 | 154.5 Million EUR | 21.65% |
| 2014 Q3 | 145.5 Million EUR | -5.83% |
| 2014 Q2 | 154.5 Million EUR | 0.0% |
| 2014 Q4 | 145.5 Million EUR | 0.0% |
| 2014 FY | - EUR | -20.64% |
| 2013 Q3 | 127 Million EUR | -12.41% |
| 2013 Q1 | 145 Million EUR | 0.0% |
| 2013 FY | - EUR | 19.94% |
| 2013 Q4 | 127 Million EUR | 0.0% |
| 2013 Q2 | 145 Million EUR | 0.0% |
| 2012 FY | - EUR | -16.62% |
| 2011 FY | - EUR | 2.05% |
| 2010 FY | - EUR | -44.41% |
| 2009 FY | - EUR | 74.63% |
| 2008 FY | - EUR | 6.96% |
| 2007 FY | - EUR | 0.28% |
| 2006 FY | - EUR | 18.98% |
| 2005 FY | - EUR | -28.88% |
| 2004 FY | - EUR | 4.01% |
| 2003 FY | - EUR | -15.45% |
| 2002 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 1886.418% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 21503.601% |
| SQZ Biotechnologies Company | -64.14 Million USD | 2078.454% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 7405.699% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | -1249.453% |
| Mesoblast Limited | -62.38 Million USD | 2133.988% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 82714.552% |
| Genus plc | 73.7 Million USD | -1621.845% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 19293.78% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 35876.733% |
| Marizyme, Inc. | -34.28 Million USD | 3801.708% |
| ContraFect Corporation | -64.99 Million USD | 2052.338% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 14566.484% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 28136.795% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 90625.949% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 48087.33% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 54708.36% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 245058.942% |
| Accustem Sciences Inc. | -3.74 Million USD | 33972.346% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 2731.306% |
| EV Biologics, Inc. | -1.26 Million USD | 100247.42% |
| Q BioMed Inc. | -617.62 Thousand USD | 205563.483% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -35426.316% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 200762.233% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 55648.527% |
| Biomind Labs Inc. | -1.03 Million USD | 122762.146% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 9.87 Million USD | -12748.031% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 17820.308% |
| Skye Bioscience, Inc. | -13.54 Million USD | 9467.007% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 85415.972% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 5076100.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 32769.811% |
| IMV Inc. | -35.52 Million USD | 3672.294% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 8096.352% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 50820.195% |
| GB Sciences, Inc. | -1.41 Million USD | 89473.435% |
| Alpha Cognition Inc. | -9.7 Million USD | 13174.924% |
| HST Global, Inc. | -5303.00 USD | 23929951.028% |
| CSL Limited | 4.78 Billion USD | 73.502% |
| Halberd Corporation | -74.27 Thousand USD | 1708523.646% |
| Enzolytics Inc. | -2.12 Million USD | 59901.256% |
| Resverlogix Corp. | -11.74 Million USD | 10907.358% |
| Affymax, Inc. | -14.29 Million USD | 8977.23% |
| SYBLEU INC | -141.57 Thousand USD | 896470.019% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 41529.754% |
| argenx SE | -216.02 Million USD | 687.437% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 2393.139% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -104172.802% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 84761.747% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -334866.371% |
| AVAX Technologies, Inc. | -6.11 Million USD | 20860.251% |
| Zenith Capital Corp. | -8.6 Million USD | 14845.526% |
| Genscript Biotech Corporation | -248.71 Million USD | 610.213% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 7284412.037% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 51970.845% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 721022.945% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 3301.566% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 43974.722% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 121383.135% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -18872594.825% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 72614.327% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 66162.405% |
| BioStem Technologies, Inc. | -7.55 Million USD | 16899.836% |
| ONE Bio Corp. | 13.61 Million USD | -9221.942% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 700864.269% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 61791.784% |
| Agentix Corp. | -1.37 Million USD | 92609.163% |
| LadRx Corporation | 412.28 Thousand USD | -307698.284% |
| Cell Source, Inc. | -4.27 Million USD | 29801.399% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 345668.472% |
| Regen BioPharma, Inc. | 1.46 Million USD | -86464.672% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 135539.602% |
| NovAccess Global Inc. | -1.03 Million USD | 122732.748% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | -14232.827% |
| Itoco Inc. | -1.86 Million USD | 67997.453% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 334381.65% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 113809.677% |
| Kadimastem Ltd | -2.62 Million USD | 48454.26% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 530729.312% |
| CytoDyn Inc. | -18.02 Million USD | 7138.66% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 1605839.665% |
| Mobile Lads Corp. | -2.24 Million USD | 56722.489% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 10377072.77% |
| Qrons Inc. | -40.08 Thousand USD | 3166188.67% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 261384.225% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -240499.28% |
| Rebus Holdings, Inc. | -951 Thousand USD | 133538.486% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 119590.4% |
| International Stem Cell Corporation | 202 Thousand USD | -628117.822% |
| Bioxytran, Inc. | -3.82 Million USD | 33318.617% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 2410814.286% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 51644.884% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 3637.874% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 2820100.0% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 46447.699% |
| Neutra Corp. | -181.24 Thousand USD | 700249.52% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 6394.955% |
| PureTech Health plc | -11.62 Million USD | 11014.251% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 6395.387% |
| IXICO plc | -707 Thousand USD | 179590.806% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 16612.687% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 2724.829% |
| CSL Limited | 4.73 Billion USD | 73.188% |
| Cellectis S.A. | -92.63 Million USD | 1469.878% |